Curtis Nickel, MD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (General Urology)
    Ineligible company: 
    HengRui
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/28/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (General Urology)
    Ineligible company: 
    Valensa
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/28/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (General Urology)
    Ineligible company: 
    Inmunotek
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/28/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (General Urology)
    Ineligible company: 
    MicroGenDx
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/28/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (General Urology)
    Ineligible company: 
    TEVA
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/28/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (General Urology)
    Ineligible company: 
    RedLeaf Medical
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/28/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (General Urology)
    Ineligible company: 
    Alivio Therapeutics
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/28/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (General Urology)
    Ineligible company: 
    Seikagaku Corporation
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/28/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (General Urology)
    Ineligible company: 
    Farr Laboratories
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/28/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (General Urology)
    Ineligible company: 
    UTIVA
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    06/28/2022

Pages

Return to Update Series (2022) Lesson 21: The Changing Role of Fluoroquinolones for Prophylaxis and Treatment of Urological Infections